Topline results from the COMPETE trial showed that ITM-11 met the study’s primary end point of PFS in inoperable, progressive ...

Topline results from the COMPETE trial showed that ITM-11 met the study’s primary end point of PFS in inoperable, progressive grade 1 or grade 2 GEP-NETs.

After a second breast cancer diagnosis at 61, I faced 17 rounds of chemo, surgery and radiation, changing my perspective on life and leading to a new normal.

A Breakdown of Trial Data that Led to the Subcutaneous Opdivo FDA Approval ...

A Breakdown of Trial Data that Led to the Subcutaneous Opdivo FDA Approval ...

A Breakdown of Trial Data that Led to the Subcutaneous Opdivo FDA Approval ...

A Breakdown of Trial Data that Led to the Subcutaneous Opdivo FDA Approval ...

A Breakdown of Trial Data that Led to the Subcutaneous Opdivo FDA Approval ...

A Breakdown of Trial Data that Led to the Subcutaneous Opdivo FDA Approval ...

A phase 3 trial is evaluating ASP-1929 photoimmunotherapy plus Keytruda in first-line treatment for recurrent head and neck ...

BCG therapy is associated with a high frequency of side effects in NMIBC; however, when used in sequential combination with ...

Hope is crucial for those of us with chronic lymphocytic leukemia, or any cancer, helping us navigate the disease's ...